Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage (Part 2)

Biopharmaceutical manufacturing has entered 2026 with a mounting workforce crisis that directly threatens global capacity, Eric Langer, president and managing partner of BioPlan Associates, stresses in an interview with BioPharm International®. For more than 15 years, hiring difficulties have been a major constraint, and current data from BioPlan Associates’ annual biopharma study show that the situation is not improving.

The industry’s rapid growth—especially in advanced modalities like cell and gene therapies and viral vector manufacturing—is outpacing the supply of skilled professionals needed to run and scale these operations, according to Langer.

Видео Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage (Part 2) канала BioPharm International